Intellia Therapeutics (NTLA) Depreciation & Amortization (CF) (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Depreciation & Amortization (CF) data on file, last reported at $2.2 million in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 11.93% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $9.5 million, a 7.77% decrease from a year earlier, with the FY2025 full-year figure at $9.8 million, down 5.04% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $2.2 million, down from $2.4 million in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for NTLA reached as high as $2.6 million in Q2 2024 and fell as low as $1.8 million in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $2.3 million across 5 years, with a median of $2.4 million in 2025.
• Across the five-year window, Depreciation & Amortization (CF) climbed 21.95% in 2024 and fell 11.93% in 2026, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $2.1 million in 2022, then climbed by 19.77% to $2.5 million in 2023, then climbed by 4.06% to $2.6 million in 2024, then slipped by 7.76% to $2.4 million in 2025, then declined by 7.06% to $2.2 million in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $2.2 million in Q1 2026, $2.4 million in Q4 2025, and $2.4 million in Q3 2025.